Like therapeutics, diagnosis and pathology verticals are also witnessing major transformations in the medical fraternity. The emergence of digital slides is strongly backed by concurrent developments across telemedicine and teleconsultation. Advances such as Whole Slide Imaging and AI are paving way for further advances such as image recognition and deep learning. In present times, AI-backed pathology operations are likely to transform diagnostics, eliminating bottlenecks such as human error probabilities. One of the most vital benefits of AI-powered digital pathology is governed by an automated implementation. Tedious tasks and repetitive jobs can be accurately performed seamlessly with automation. Several studies are vouching for the efficiency of AI-powered digital pathology to diagnose accurately, possible malignant regions. AI-based cancer diagnosis renders high efficiency, of over 92%, thereby significantly propelling advances in oncology diagnosis as well as eventual therapeutics, besides easing off manual labor.
To improvise recovery provisions in oncology, early diagnosis is considered advertently crucial. To offset functional challenges such as time constraints in deriving accuracy in early diagnosis, AI reliance is likely to witness encouraging adoption eying high productivity. AI-based digital pathology can accentuate diagnosis, thereby improving eventual therapeutics. In a recent development, NVIDIA has received Breakthrough Designation granted by the US FDA. This is been a pioneering venture for AI in cancer diagnosis. NVIDA DGX-1 systems have been phenomenal in detecting prostate cancer.
Leading Pathology Labs Going Digital: Dominant Trend across Developed Economies
Besides diagnosis, digital pathology also enables data sharing owing to improved benefits such as network potential and affordable storage systems. Image analysis is very vital for improved diagnostic output. Implementation of AI in digital pathology is likely to be further improved by image analysis and machine learning capabilities. Matured economies such as the UK are going lengths to transform image analysis tools in digital pathology. In this light, NCRI Cellular Molecular Pathology and British in Vitro Diagnostics have collaborated to carve new tools to aid digital pathology outcome.
In a recent development, top-notch diagnostic and pathology center, Alverno Laboratories has affirmed its digital transformation in pathology capabilities. Hence, Alverno Laboratories will collaborate with Philips to access its Intellisite Pathology which essentially is a digital pathology platform. The decision resonates with Alverno’s endeavors to ensure superlative laboratory outcomes and patient safety. Factors as such are likely to draw far-fetched growth opportunities in digital pathology. Improved pathology capabilities play a crucial part in harnessing disease diagnostics, more emphatically for critical disease occurrences such as cancer diagnostics.
Yet another development in AI-based diagnostics is PathAI’s advanced machine learning capabilities to improve diagnostic outcomes. The company has recently affirmed its fundraising initiatives, amassing a total of $60 million in order to spearhead far-fetched R&D expeditions in device technology for the improved diagnostic outcome. In yet another recent development, ace market participant, Align Technology has come up with its latest designs in digital scanners, under the brands, Next-Generation iTero Element 2 and New iTero Element Flex to rev up its digital pathology offerings.
1,072 total views, 3 views today